HRMY - Harmony Biosciences Holdings Inc

-

$undefined

N/A

(N/A)

Harmony Biosciences Holdings Inc NasdaqGM:HRMY Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Location: 630 West Germantown Pike, Plymouth Meeting, PA, 19462, United States | Website: https://www.harmonybiosciences.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.626B

Cash

507M

Avg Qtr Burn

N/A

Short % of Float

5.74%

Insider Ownership

11.64%

Institutional Own.

92.94%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
WAKIX® (pitolisant) Details
Excessive daytime sleepiness, Genetic disorder, Cataplexy, Narcolepsy, Prader-Willi syndrome

Approved

Quarterly sales

Approved

Quarterly sales

WAKIX® (pitolisant) Details
Rare genetic disease, Genetic disorder, Prader-Willi syndrome, Excessive daytime sleepiness

Phase 3

Data readout

Zygel (ZYN002 CBD Gel) Details
Rare genetic disease, Genetic disorder, Fragile X syndrome

Phase 3

Data readout

Zygel (ZYN002 CBD Gel) Details
Rare genetic disease, Genetic disorder, Deletion Syndrome , 22q11.2 deletion syndrome

Phase 3

Initiation

WAKIX® (pitolisant) Details
EDS in Idiopathic Hypersomnia

Phase 3

Initiation

Phase 2

Data readout

WAKIX® (pitolisant) Details
Muscle weakness, Muscle degeneration, Myotonic Dystrophy Type 1

Phase 2

Update

TPM-1116 [orexin-2 receptor agonist] Details
Narcolepsy, Sleep-wake disorder

IND

Submission